| BackgroundBronchial asthma is a common and risky respiratory chronic disease.In recent decades,with the development of industrialization and urbanization,the aggravation of air pollution and the change of living environment,the prevalence of bronchial asthma shows an increasing trend,among which mild asthma patients account for the largest proportion.Bronchial asthma is characterized by chronic inflammation of the airways,so the use of anti-inflammatory drugs is essential for well control of asthma.Inhaled glucocorticoids are the first chosen to treat asthma.While patients with mild asthma are often reluctant to take anti-inflammatory drugs and use only relievers such as albuterol,because of their mild symptoms,lack of awareness of asthma and concerns about treatment side effects.Overuse of asthma relievers without anti-inflammatory treatment will increases the risk of acute exacerbations of asthma and leads to a gradual decline in lung function.Therefore,in order to solve the contradictions in the treatment of patients with mild asthma and improve their adherence,the as-needed use of budesonide formoterol inhalant as a new treatment has attracted increasing attention.ObjectiveThe purpose of this study is to analyze the efficacy and safety of three therapeutic regimens:as-needed inhaling budesonide-formoterol,as-needed inhaling albuterol and regular inhaling budesonide-formoterol in the prevention of asthma exacerbations,improvement of asthma control and improvement of lung function in patients with mild bronchial asthma.Methods73 cases of mild asthma(48 males and 25 females,ages 19-65 years)diagnosed in the department of respiratory and critical care medicine(PCCM)of the Shandong Provincial Qianfoshan Hospital,Shandong University from May 2018 to January 2019 were selected.The patients were randomly divided into groups A,B and C.Group A received as-needed inhaling albuterol,group B received as-needed inhaling budesonide-formoterol,and group C received regular inhaling budesonide-formoterol for a total of 52 weeks.,followed by telephone,and at the end of the observation period,patients revisited at the hospital.The annualized exacerbation rate,asthma control test(ACT),the weeks with well-controlled asthma and adverse reactions were compared between the three groups,and the FeNO value and lung function before and after treatment were measured.Results1.In terms of annual acute attack rate,the difference between group B and group C was not statistically significant(P>0.05),which was lower than that of group A(P<0.05).2.In terms of ACT score,FeNO value and lung function indicators,there was no statistically significant difference in group A before and after treatment(P>0.05).Group B and C showed significant improvement after treatment compared with group A,and were better than group A,with statistically significant differences(P<0.05).3.There were significant differences among the three groups in the weeks of well controlled asthma,among which group C was better than group B,group B was better than group A(P<0.05).4.In terms of safety,there was no significant difference in the incidence of adverse reactions between the groups(P>0.05),and no serious adverse events occurred.ConclusionAs-needed inhaling budesonide-formoterol is more effective in improving symptoms,reducing the incidence of asthma exacerbation,enhancing the quality of life,and preventing lung function decline with good security,compared to traditional inhaled albuterol in mild asthma,and the effect is similar to that of regular inhalation of budesonide formoterol. |
PDF Full Text Request